NIH grant Patent on the LAPP Micro-Probe
Lenox Laser has had the privilege of partnering with the NYU Langone Medical Center through Nandor Ludvig, M.D., Ph.D. Dr. Ludvig serves as the Research Associate Professor for the Department of Neurology at NYU's School of Medicine and he has published 35 peer-reviewed journals and five book chapters on the subject of epilepsy and cognitive neuroscience. Dr. Ludvig has built relationships with Lenox Laser's President, Joe d'Entremont, and Director of Engineering, Gregory Solyar.
In 2005, Lenox Laser and Dr. Ludvig collaborated on a Phase I patent application for a Laser-Perforated Intra-Parenchymal Micro-Probe titled: “Apparatus and Method for Monitoring and Treatment of Brain Disorders”. The invention applies to the medical and neuroscience instrumentation fields for research, clinical diagnostics, and therapy. This patent pertains to the apparatus and methods in which very small volumes of biological fluid-borne material, particularly large molecules such as proteins, may be selectively extracted from or delivered to interstitial fluid (either in vivo or in vitro) by means of intra-parenchymal micro-probes inserted in the brain. The Lenox Laser Corporation is listed as the original assignee, and Dr. Ludvig is listed as the inventor alongside Lenox Laser's former Chief Electro-Optical Engineer, Walter Blumenfeld, Lorant Kovacs, Ruben I. Kuzniecky, Orrin Devinsky, Werner Doyle, and Geza Medveczky. The patent for this invention was made possible through the aid of NIH (National Institute of Health) grants. Through NIH SBIR (Small Business Innovation Research) funding, the product will be abbreviated to the “LAPP” micro-probe, standing for Laser-perforated and Push-pull Perfused.
Phase II grant projects will refine the product for commercialization and present its unique capabilities to scientists and physicians. In preparation of in vivo studies to be conducted in Phase II, a rat was implanted with a LAPP micro-probe in the right hippocampus. The LAPP was not used for collecting or delivering proteins because this exceeds Phase I proceedings, but success was found in simply gauging the function of the micro-probe implanted, in vivo, in a freely moving rat for six hours with no deterioration in local EEG activity. This indicated that the LAPP can be safely used in neural tissue. The rat was then administered an epileptogenic compound, (NMDA)- proven to cause characteristic seizures- via the LAPP micro-probe, and the rat did experience limbic seizures, proof of the LAPP method to successfully deliver compounds into the brain. No humans were used for testing, only rats.
Lenox Laser Medical, LLC's involvement in critical medical research and the invention/ production of groundbreaking tools has marked a clear niche for our expertise in small hole laser drilling and exact leaks in biotechnology research devices.
The LAPP Micro-probe is pictured above.
(All technical information in this post written by Ludvig, Blumenfeld, Gidner, Vehmas, and Medveczky, 2005.)